Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization

Abstract

Bevacizumab treatment was found to be efficacious in the treatment of myopic CNV, resulting in stable gains in visual acuity lasting at least 42 months, without any adverse ocular or general events. Myopic CNV size was identified as a significant prognostic factor.

Response to the letter to the editor entitled "Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization"

“…A limitation of our study was the lack of evaluation of any OCT changes [1]. We agree with Chew and Tan that important additional information could have been provided by such an evaluation.…”

“…Dear Editor, We thank Chew and Tan for their interest in our recent article in Graefe's Archive for Clinical and Experimental Ophthalmology [1].…”

Letter to the editor: Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization

“…In that series, mean LogMAR VA of 0.26 was achieved at 24 months [3]. Furthermore, while anti-VEGF therapy has been shown to be effective [1], it is also associated with both ocular and systemic risks [4] such as endophthalmitis and cerebrovascular accidents. For patients who are unwilling to accept the risk of anti-VEGF therapy, we believe that PDT is a viable alternative to consider [3].…”

“…al. [1] reporting the long-term visual outcomes of treatment-naïve myopic choroidal neovascularization (mCNV) treated with intravitreal bevcizumab injections. Their results are impressive, demonstrating stable gains in visual acuity lasting up to 42 months following treatment.…”

“…The authors also mentioned that switching from TimeDomain OCT (TD-OCT) (Stratus OCT, Carl Zeiss Meditec Inc., Dublin, CA, USA) to Spectral-Domain OCT (SD-OCT) (Cirrus OCT, Carl Zeiss Meditec Inc.) was the main limitation in excluding Central Subfield Thickness (CST) as a secondary outcome measure [1]. Several studies have described manual adjustment of the SD-OCT segmentation lines [5] or the use of conversion equations [6] that reliably achieved retinal thickness measurements comparable to that of TD-OCT.…”